In this study, TMT proteomics technology was used to screen out 44 potential protein targets of LIRA in the treatment of IGT, including TBC1D13, PPIF, MPRIP, ME2, CYP51, DAD1, PTPA, TXNL1, ATG2B, BCL-2, etc., suggesting that these target proteins may be associated with insulin resistance, islet beta cell insufficiency, etc. At the same time, LIRA can change the expression of the above differential proteins, making them more likely to be in the blank group. The gene discussed is MPRIP; the disease is Insulin resistance.